Comparative study of effect of duloxetine on bone metabolism in patients with depressive disorder

doi:10.3877/cma.j.issn.1674-0785.2022.08.005

Abstract

Abstract:

Objective

To evaluate the effect of the antidepressant duloxetine on bone metabolism in patients with depression by comparing the blood concentration of bone turnover markers.

Methods

From September 2020 to February 2022, 49 patients with depressive disorder (patient group) and 49 sex- and age-matched healthy controls (normal group) were recruited at the Department of Clinical Psychology of Wuxi Hospital of Traditional Chinese Medicine and the Department of Clinical Psychology of Wuxi Mental Health Center. Blood concentrations of bone transformation markers including C-terminal cross-linking telopeptide of type I collagen (β-CTX) and N-terminal propeptide of type I procollagen (P1NP) were detected by electrochemiluminescence immunoassay. Comparisons were performed between the patient group and the normal group, and between patients before and after treatment with duloxetine.

Results

At baseline, β-CTX (pg/ml) was significantly higher in the patient group than in the normal group [321.1 (189.4) vs 210.4 (103.5), t=-3.59, P=0.001], but there was no significant difference in P1NP (P＞0.05). After treatment, β-CTX increased significantly from 321.1 (189.4) to 475.3 (192.4) in the patient group (P=0.001); P1NP increased from 49.9(19.8) to 54.5(27.6), but there was no significant difference.

Conclusion

Bone resorption in patients with depression is higher than that in healthy people, and it is more obvious after treatment with duloxetine, which may increase the risk of fracture.

Key words: Depressive disorder, Duloxetine, Bone turnover marker

Xiaoyan Xu, Zouqing Lin, Kai Zhang, Zhiqun Cha, Feng Yi, Leiming Cao, Guoqiang Wang. Comparative study of effect of duloxetine on bone metabolism in patients with depressive disorder[J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(08): 732-737.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2022.08.005

https://zhlcyszz.cma-cmc.com.cn/EN/Y2022/V16/I08/732

Figures/Tables 8

References 24

1	Huang Y, Wang Y, Wang H, et al Prevalence of mental disorders in China: a cross-sectional epidemiological study [J]. Lancet Psychiatry, 2019, 6(3): 211-224.
2	Schweiger U, Weber B, Deuschle M, et al. Lumbar bone mineral density in patients with major depression: evidence of increased bone loss at follow-up [J]. Am J Psychiatry. 2000 Jan;157(1):118-20.
3	Cizza G, Primma S, Coyle M, et al. Depression and osteoporosis: a research synthesis with meta-analysis [J]. Horm Metab Res, 2010, 42(7): 467-82.
4	Wu Q, Liu B, Tonmoy S. Depression and risk of fracture and bone loss: an updated meta-analysis of prospective studies [J]. Osteoporos Int, 2018, 29(6): 1303-1312.
5	Cesari M, Landi F, Torre S, et al. Prevalence and risk factors for falls in an older community-dwelling population [J]. J Gerontol A Biol Sci Med Sci, 2002 Nov;57(11):M722-M726.
6	Coelho R, Silva C, Maia A, et al. Bone mineral density and depression: a community study in women [J]. J Psychosom Res, 1999, 46(1): 29-35.
7	Nandam LS, Brazel M, Zhou M, et al. Cortisol and major depressive disorder-translating findings from humans to animal models and back [J]. Front Psychiatry, 2020, 10: 974.
8	Altindag O, Altindag A, Asoglu M, et al. Relation of cortisol levels and bone mineral density among premenopausal women with major depression [J]. Int J Clin Pract, 2007, 61(3): 416-420.
9	Eom CS, Lee HK, Ye S, et al. Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis [J]. J Bone Miner Res, 2012, 27(5): 1186-1195.
10	Rauma PH, Honkanen RJ, Williams LJ, et al. Effects of antidepressants on postmenopausal bone loss- A 5-year longitudinal study from the OSTPRE cohort [J]. Bone, 2016, 89: 25-31.
11	Ziere G, Dieleman JP, van der Cammen TJ, et al. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures [J]. J Clin Psychopharmacol, 2008, 28(4): 411-417.
12	Petronijević M, Petronijević N, Ivković M, et al. Low bone mineral density and high bone metabolism turnover in premenopausal women with unipolar depression [J]. Bone, 2008, 42(3): 582-590.
13	Shea ML, Garfield LD, Teitelbaum S, et al. Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption [J]. Osteoporos Int, 2013, 24(5): 1741-1749.
14	Shea ML, Garfield LD, Teitelbaum S, et al. Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption [J]. Osteoporos Int, 2013, 24(5): 1741-1749.
15	Aydin H, Mutlu N, Akbas NB. Treatment of a major depression episode suppresses markers of bone turnover in premenopausal women [J]. J Psychiatr Res, 2011, 45(10): 1316-1320.
16	Warden SJ, Hassett SM, Bond JL, et al. Psychotropic drugs have contrasting skeletal effects that are independent of their effects on physical activity levels [J]. Bone, 2010, 46(4): 985-992.
17	Bonnet N, Bernard P, Beaupied H, et al. Various effects of antidepressant drugs on bone microarchitectecture, mechanical properties and bone remodeling [J]. Toxicol Appl Pharmacol, 2007, 221(1): 111-118.
18	Cauley JA, Fullman RL, Stone KL, et al; Mr. OS Research Group. Factors associated with the lumbar spine and proximal femur bone mineral density in older men [J]. Osteoporos Int, 2005, 16(12): 1525-1537.
19	Bolton JM, Targownik LE, Leung S, et al. Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women [J]. J Clin Psychopharmacol, 2011, 31(1): 56-60.
20	Garfield LD, Müller DJ, Kennedy JL, et al. Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults [J]. World J Biol Psychiatry, 2014, 15(5): 404-410.
21	Haney EM, Warden SJ, Bliziotes MM. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? [J] Bone, 2010, 46(1): 13-17.
22	Gustafsson BI, Thommesen L, Stunes AK, et al. Serotonin and fluoxetine modulate bone cell function in vitro [J]. J Cell Biochem, 2006, 98(1): 139-151.
23	Battaglino R, Fu J, Späte U, et al. Serotonin regulates osteoclast differentiation through its transporter [J]. J Bone Miner Res, 2004, 19(9): 1420-1431.
24	Warden SJ, Robling AG, Sanders MS, et al. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth [J]. Endocrinology, 2005, 146(2): 685-693.

项目	患者组（n=49）	对照组（n=49）	t/χ²值	P值
男/女	18/31	26/23	2.64	0.104
年龄（岁）	29.65（7.50）	31.85（6.22）	-1.58	0.116

项目	患者组（n=49）	对照组（n=49）	t/χ²值	P值
男/女	18/31	26/23	2.64	0.104
年龄（岁）	29.65（7.50）	31.85（6.22）	-1.58	0.116

分组	时间点
分组	基线	4周末	8周末
患者组（n=49）
β-CTX（pg/ml）	321.1（189.4）	411.9（196.7）	475.3±192.4
P1NP（ng/ml）	49.9（19.8）	65.2（44.3）	54.5±27.6
对照组（n=49）
β-CTX（pg/ml）	210.4（103.5）	-	-
P1NP（ng/ml）	52.3（36.6）	-	-

分组	时间点
分组	基线	4周末	8周末
患者组（n=49）
β-CTX（pg/ml）	321.1（189.4）	411.9（196.7）	475.3±192.4
P1NP（ng/ml）	49.9（19.8）	65.2（44.3）	54.5±27.6
对照组（n=49）
β-CTX（pg/ml）	210.4（103.5）	-	-
P1NP（ng/ml）	52.3（36.6）	-	-

[1]	Zheming Bao, Qing Shan, Chen Li, Mengli Chen. Advancement of duloxetine in treatment of osteoarthritis pain [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2021, 15(03): 318-323.
[2]	Huanrui Sun, Ruopeng Zhang. Recurrent spontaneous abortion and the imbalance of gut microbiota [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2022, 18(05): 506-511.
[3]	Yan Hu, Weihua Wang, Juying Ji, Rong Zhou, Yu Liu, Yunchuan Sui, hanqing Zhao, Yifan Hu. Clinical effects of venlafaxine initially combined with tandospirone for treatment of major depressive disorder [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(08): 725-731.
[4]	Zouqing Lin, Xiaoyan Xu, Leiming Cao, Zhiqiang Wang, Guoqiang Wang, Kai Zhang. Efficacy and safety of S-ketamine in treatment of major depressive disorder [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(08): 719-724.
[5]	Hui Zhang, Caifeng Yan, Shangyong Feng, Lu Tan, Yingying Ruan, Yihui Gong. Type 2 diabetic osteoporosis: risk factors and early diagnosis by quantitative CT [J]. Chinese Journal of Clinicians(Electronic Edition), 2020, 14(08): 613-618.
[6]	Luyi Huang, Jun He. Clinical application of the acupuncture treatment of " unblocking the conception vessel and regulating qi" [J]. Chinese Journal of Acupuncture and Moxibustion(Electronic Edition), 2018, 07(01): 34-36.
[7]	Minghui Chen, Gongying Li. Early diagnosis and literature review of soft bipolarity [J]. Chinese Journal of Diagnostics(Electronic Edition), 2018, 06(04): 256-259.
[8]	Shen Li, Jie Li, Hongjun Tian, Leemon Albert, Martin Walter, Chuanjun Zhuo. Effect of treatment time on antidepressant effect of ketamine: current research status and future directions [J]. Chinese Journal of Diagnostics(Electronic Edition), 2018, 06(03): 151-156.
[9]	Yanjun Tian, Chuanxin Liu, Haiqing Liu, Bo Bai. The recent advances in genome-wide association studies of depression [J]. Chinese Journal of Diagnostics(Electronic Edition), 2017, 05(02): 140-143.

Please choose a citation manager

Content to export